Leading Proxy Advisory Firms Recommend That Discovery Labs' Stockholders Vote "FOR" Important Proposals at Annual Meeting of Stockholders
07 déc. 2010 06h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Dec. 7, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today that two independent proxy advisory firms, ISS Proxy Advisory Services ("ISS") and Glass,...
Discovery Labs Receives Nasdaq Delisting Notification Related to Minimum Bid Price and Plans to File Request for Hearing
03 déc. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Dec. 3, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), announced today that, on November 30, 2010, the Company received a Staff Determination letter from The...
Discovery Labs to Present at the Lazard Capital Markets Healthcare Conference
15 nov. 2010 07h30 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Nov. 15, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related...
Discovery Labs Provides a Third Quarter 2010 Business and Financial Update
09 nov. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Nov. 9, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related...
Discovery Labs Announces Pipeline and Business Update Conference Call
02 nov. 2010 17h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Nov. 2, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced today that it will be hosting a conference call on Tuesday, November 9, 2010, at 10:00 AM EST....
Discovery Labs' KL4 Surfactant Granted Orphan Drug Designation for the Treatment of Cystic Fibrosis
01 nov. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Nov. 1, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), today announced that the Office of Orphan Products Development of the United States Food and Drug...
Discovery Labs Announces Presentation & Key Results of Phase 2a Study of Aerosolized KL4 Surfactant in Cystic Fibrosis at the North American Cystic Fibrosis Conference
22 oct. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Oct. 22, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announces that the Phase 2a clinical study of aerosolized KL4 surfactant (lucinactant) in patients...
Discovery Labs Announces Completion of Phase 2a Study of Aerosolized KL4 Surfactant in Cystic Fibrosis
15 oct. 2010 08h00 HE
|
Discovery Laboratories, Inc.
Aerosolized KL4 Surfactant Generally Safe and Well Tolerated in Phase 2a Trial – Supports Feasibility of Delivering Aerosolized KL4 Surfactant to Patients With Cystic Fibrosis
Results to be...
Discovery Labs Appoints W. Thomas Amick as Chief Executive Officer
15 oct. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Oct. 15, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a biotechnology company developing its novel synthetic surfactant and aerosol technologies for...
PharmaBio Expands Investment in Discovery Labs to Advance Surfaxin LS(TM) and Aerosurf(R) Programs
13 oct. 2010 07h30 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., Oct. 13, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a biotechnology company developing its novel synthetic surfactant and aerosol technologies for...